A comprehensive meta-analysis has demonstrated that colchicine, long used for the treatment of gout, can significantly reduce the probability of myocardial infarction and acute cerebrovascular accident (stroke) in individuals suffering from cardiovascular diseases. Specialists summarized the results of twelve clinical studies involving approximately twenty-three thousand individuals. All participants were prescribed a daily dose of 0.5 mg of the drug, to be taken once or twice a day for at least six months. The collected and processed information indicates the following: in the cohort taking colchicine, there were eight fewer heart attacks and nine fewer strokes per thousand subjects compared to the control group. Scientists attribute this result to the potent anti-inflammatory effect of the medication, which leads to a reduction in systemic inflammatory processes—the main trigger for the development of atherosclerosis and serious vascular problems. Doctors found no significant adverse events. A small proportion of subjects experienced temporary digestive discomfort, which subsided spontaneously. Specialists believe that low-dose colchicine holds significant potential in preventive medicine but emphasize the need for continued scientific investigation.
About the Author
